We compared the absorption of three formulations of ciprofloxacin after oral administration in 18 normal adult male volunteers. Each subject received 500 mg of ciprofloxacin as two 250-mg tablets, one 500-mg tablet, or a solution in a randomized crossover sequence. Pharmacokinetic parameters were determined by model independent methods. Because a solution is considered to be the ideal oral dosage form, the results determined for the tablets were compared to those for the solution. Mean values for the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, and the elimination half-life were 3.23 ,ug/ml, 1.00 h, and 5.04 h, respectively, for the solution. The mean renal clearance of ciprofloxacin was 372 ml/min and accounted for at least 50% of the total clearance. We recovered 44.4, 48.6, and 55.8% of the administered ciprofloxacin from the urine as unchanged drug within 24 h after dosing with the 250-mg tablets, 500-mg tablets, or solution, respectively. The 500-mg tablets were found to be bioequivalent to the solution with regard to all pharmacokinetic parameters. The 250-mg tablet was not bioequivalent to either of the other formulations; the relative bioavailability values were 78.7 and 74.1%, respectively, for the 500-mg tablet and the solution. The clinical significance of this difference in bioavailability is yet to be determined.
Ciprofloxacin is a quinoline carboxylic acid which possesses superior activity in vitro in comparison to other quinoline carboxylic acids against both gram-positive and gram-negative organisms. Its antimicrobial spectrum includes activity against aminoglycoside-and cephalosporinresistant Enterobacteriaceae organisms, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (1, 3, 6, 8) .
Ciprofloxacin is water soluble and can be formulated as a solution or as a tablet. Since absorption is not reduced or delayed by disintegration or dissolution, a solution is considered the optimal oral dosage form to which other forms are compared. Slower or less-complete absorption of tablets may result in lower peak antibiotic concentrations in the serum or a shorter time during which the serum concentration exceeds the MIC of a susceptible organism. Because of the lack of studies done in children, there are no plans to manufacture the solution formulation of ciprofloxacin at this time. The purpose of this study was (20 ,ul) was injected into the mobile phase at a flow rate of 2.0 ml/min. The assay was linear for concentrations varying from 5 ng/ml to 5 ,ug/ml. The sensitivity limit of the assay was 5 ng/ml. The intraday coefficient of variation was 1.8% for the high control (500 ng/ml) and 3.1% for the low control (100 ng/ml); the interday coefficient of variation was 7.2% for the high control and 7.9% for the low control.
Pharmacokinetic analysis. Pharmacokinetic analysis was performed by using model independent methods. The terminal elimination rate constant was calculated from the slope of the line made by the logs of the 8-, 12-, and 24-h ciprofloxacin concentrations in serum divided by 2.303. The area under the concentration-versus-time curve (AUC) was calculated by using the trapezoidal rule plus the quotient obtained by dividing the last concentration in serum by the terminal elimination rate constant (5) .
Total clearance (CL) was calculated by dividing the dose by the AUC. The volume of distribution (V) during the terminal elimination phase was calculated by dividing the total clearance by the elimination rate constant. These estimations of clearance and V assume 100% bioavailability (t). In the case of an oral agent such as ciprofloxacin in which the absolute bioavailability is unknown, these equations generate estimates of CL/f and Vlf. Renal clearance was calculated by dividing the amount of unchanged drug excreted in the urine in the first 24 h after drug administration by the AUC during that time interval. The bioavailability of the tablets compared to the solution was calculated by dividing the AUC for the tablet by the AUC for the solution (5) .
Statistical analysis. Statistical analysis of the data was performed by using analysis of variance (ANOVA) for repeated measures. Observations found to vary to a significant extent were further tested by Tukey's A test to determine differences between formulations (7). Probability values of <0.05 were considered significant.
RESULTS
Ciprofloxacin was well tolerated in all subjects after oral administration of each dosage form. No subjects reported any adverse effects, and physical examinations and labortory studies done at the completion of the protocol were within normal limits.
The mean concentrations in serum for each formulation from 0 to 24 h are shown in Fig. 1 . Urinary excretion data is listed in Table 1 . Ciprofloxacin was rapidly absorbed after oral administration of all three dosage forms, and significant concentrations were achieved in the urine in the first 2 h after dosing.
Multivariate analysis was conducted for the following parameters: maximum concentration of drug in serum, time to maximum concentration of drug in serum, AUC, elimination half-life, elimination rate constant, V, total clearance, renal clearance, urinary recovery of unchanged drug, and concentration in saliva. The results of these analyses are shown in Table 2 . When significant variation due to dosage form was observed, a posteriori testing (using Tukey's A test) was performed to identify differences between formulations. The time to maximum concentration of drug in serum, concentration in the saliva, elimination rate constant, and renal clearance were not influenced by dosage form. Although higher maximum concentrations were achieved with the solution, this was not statistically different from the other formulations. The 500-mg tablets were not found to be statistically different from the solution in any pharmacokinetic parameter. The Vlf and the nonrenal clearance/bioavailability (CLNR/I) (defined as CL/f minus renal clearance) were significantly greater, and the AUC and the amount of unchanged drug excreted in the urine were significantly smaller for the 250-mg tablets compared to the solution. These differences ranged from 20 to 31%. The Vlf and nonrenal clearance of the 250-mg tablets were also found to be significantly different from those of the 500-mg tablets. These differences ranged from 17 to 25% with respect to the 500-mg tablets.
The mean values and ranges for the ratio of ciprofloxacin concentration in saliva to that in serum are shown in Table 3 . These ratios varied widely between and within subjects but were not dependent on the formulation administered. Ciprofloxacin concentrations in saliva averaged 21.2% (range, 5.8 to 62.8%) of simultaneous concentrations in serum, with poorer penetration at more alkaline pHs (r = -0.2442, P < 0.0003). Ciprofloxacin concentration in saliva declined more rapidly than it did in serum; thus, the ratio of ciprofloxacin concentration in saliva to that in serum was highest early after drug ingestion (r = 0.3994, P < 0.00001). Although these correlations achieved statistical significance, only 6 and 16% of the variation of the saliva/serum concentration ratio could be explained by pH and time after dose, respectively.
DISCUSSION
Ciprofloxacin was well absorbed in all subjects after the administration of each formulation. The mean concentrations in serum from 0 to 24 h for each formulation are shown in Fig. 1 . Mean maximum concentrations in serum were between 2.83 and 3.23 ,ug/ml, which are many times greater than the MICs for most susceptible organisms.
Our data indicate that ciprofloxacin is eliminated at least 50% by the kidney as unchanged drug, with a mean renal clearance of 365 ml/min. This value is much greater than the normal rate of glomerular filtration (4) and indicates that tubular secretion contributes to renal excretion. We found no corvelation between urine flow rate and renal clearance (r = 0.0008, P = 0.63), suggesting that ciprofloxacin does not unde'rgo significant flow-dependent tubular reabsorption.
Total body clearance and V could not be reliably estimated in our subjects since the bioavailability of orally administered ciprofloxacin is unknown. In a recent report by Wise et al. (9) , the bioavailability of ciprofloxacin in five subjects was reported to be 71.7 ± 13.2% after a 500-mg oral dose and a 100-mg intravenous dose. Bioavailability was calculated by using AUC ratios corrected for dose. In that study, mean total body clearance was 34.0 liters/h after a 100-mg intravenous dose. The higher total clearance (CL/J) for all formulations found in our study suggests that ciprofloxacin was incompletely absorbed. Solving for f in our subjects using a dose-corrected AUC from the study of Wise et al. (9) yields a bioavailability of 58.9, 74.7, and 79.4% for the 250-mg tablets, the 500-mg tablets, and the solution, respectively; this is in good agreement with the Wise data for the latter two formulations.
The mean Vlfof 277 liters in our subjects after administration of the oral solution was probably also influenced by incomplete absorption. Our Vlf estimates cannot be directly compared at steady-state of 177 liters found after intravenous administration (8) , since these parameters were calculated by different methods. Nonetheless, this large V indicates that ciprofloxacin distributes to an apparent volume which is much larger than total body water (42 liters in a 70-kg adult (4) . Studies of distribution of radioactive drug in animals reveal higher concentrations in the kidney, liver, and cartilagenous tissue relative to concentrations in the rest of the body (personal communication, George Arcieri, Miles Pharmaceuticals). A similar distribution of ciprofloxacin in humans may account for the large V that has been found in studies in normal volunteers.
We also measured the ciprofloxacin content in parotid saliva. In our subjects, the mean concentration was 25.5% of the simultaneous concentration in serum. This finding cannot be explained by a high degree of plasma protein binding since ciprofloxacin is only 20% bound to plasma proteins (8) . Ciprofloxacin is a large dipolar ion (molecular weight, 348) that is poorly lipophilic (9) and thus would not be likely to diffuse into saliva. Our data indicate that ciprofloxacin content in saliva, relative to that in serum, may be greater early in the dosing interval. The reason for this is unclear; the ratio should be constant unless some process (i.e., diffusion or protein binding) is nonlinear. It was not a result of unrinsed drug left in the mouth early after dosing since we collected saliva directly from the parotid gland with the aid of a suction device, and the phenomenon occurred with tablets as well as solution.
We also found a statistically significant relationship between the concentration of ciprofloxacin in saliva and the pH. As than what has been found for blister fluid (57.9% [2] ). Unlike saliva, blister fluid represents an inflamed environment with increased capillary permeability. Blister fluid also contains plasma proteins which could result in slightly higher drug concentrations.
The 250-mg tablets were statistically different from the other formulations for the following parameters: AUC, CL/f, and Vlf. These parameters are interdependent when calculated by the methods used here and are all influenced by differences in the extent of absorption. Parameters such as elimination half-life and time to maximum concentration of drug in serum, which are not affected by the extent of absorption, were similar for all three formulations. Therefore, it can be concluded that the relative bioavailability of the 250-mg tablets is 74.1% that of the solution and 78.7% that of the 500-mg tablets. The 500-mg tablet was not statistically different from the solution in any parameter and can be considered bioequivalent.
The clinical significance of these slight differences in bioavailability between formulations is unknown at the present time. The optimal dosage regimen for ciprofloxacin is yet to be established, and these differences in bioavailability between formulations should be considered when patients are being treated with ciprofloxacin.
